Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?

被引:162
作者
Hay, ID
Grant, CS
Bergstralh, EJ
Thompson, GB
van Heerden, JA
Goellner, JR
机构
[1] Mayo Clin & Mayo Fdn, Dept Surg, Biostat Sect, Div Endocrinol & Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA
关键词
D O I
10.1016/S0039-6060(98)70035-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Controversy continues regarding the optimal extent of primary thyroid resection in most patients with papillary thyroid carcinoma (PTC), who are at minimal risk of cause-specific mortality (CSM). This study was designed to compare CSM and recurrence rates after either unilateral lobectomy (UL) or bilateral lobar resection (BLR) in patients with PTC considered low risk by AMES criteria. Methods. Outcome was studied in 1685 patients initially treated during 1940 through 1992 and followed for up to 54 postoperative years (mean, 18 years). One thousand six hundred fifty-six patients (98 %) had complete primary tumor resection; 634 (38%) had involvement of regional nodes. One hundred ninety-five patients (12 %) had UL; BLR accounted for 1468 (near-total GO %; total thyroidectomy 18%). Results. Thirty-year rates for CSM and distant metastasis were 2 % and 3 %, respectively. Twenty-year rates for local recurrence and nodal metastasis were 4% and 8%, respectively. There were no significant differences in CSM or distant metastasis rates between UL and BLR (P > .2). After UL, 20-year rates for local recurrence and nodal metastasis were 14 % and 19 %, significantly higher (P = .0001) than the 2 % and 6% rates seen after BLR Conclusions. UL war not associated with higher CSM rates, but it was associated with a significantly higher risk of locoregional recurrence. Thus BLR probably represents a preferable initial surgical approach to patients with low-risk PTC.
引用
收藏
页码:958 / 964
页数:7
相关论文
共 25 条
  • [21] Shaha AR., 1997, ONCOLOGY-BASEL, V11, P1228
  • [22] Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
    Singer, PA
    Cooper, DS
    Daniels, GH
    Ladenson, PW
    Greenspan, FS
    Levy, EG
    Braverman, LE
    Clark, OH
    McDougall, IR
    Ain, KV
    Dorfman, SG
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (19) : 2165 - 2172
  • [23] Current trends in the management of well differentiated papillary thyroid carcinoma
    Solomon, BL
    Wartofsky, L
    Burman, KD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (01) : 333 - 339
  • [24] Tsang TW, 1998, CANCER-AM CANCER SOC, V82, P375
  • [25] REPORT OF THE CONSENSUS DEVELOPMENT CONFERENCE ON THE MANAGEMENT OF DIFFERENTIATED THYROID-CANCER IN THE NETHERLANDS
    VANDEVELDE, CJH
    HAMMING, JF
    GOSLINGS, BM
    SCHELFHOUT, LJDM
    CLARK, OH
    SMEDS, S
    BRUINING, HA
    KRENNING, EP
    CADY, B
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (02): : 287 - 292